Methods for culturing immune cells
AssigneeLyell Immunopharma, Inc.
InventorsSuman Kumar VODNALA, Yogin PATEL, Nicholas P. RESTIFO
Life of this patent
Estimating the term…
Abstract
The preset disclosure provides methods of culturing TILs in a medium comprising at least about 30 mM to at least about 100 mM potassium ion. In some aspects, the methods disclosed herein enhance expansion of CD8+ TILs, relative to CD4+ TILs. In some aspects, the methods further increase the number of less-differentiated cells, e.g., less-differentiated TILs, in the population of cells. In some aspects, the methods disclosed herein enrich for tumor-reactive, e.g., tumor specific, TILs such that clonal diversity is preserved. In some aspects, the cells, e.g., the TILs, are administered to a subject in need thereof. 17667030.1
Claims38
A method of culturing tumor infiltrating lymphocytes (TILs) ex vivo or in vitro comprising placing a heterogeneous population of TILs in a metabolic reprogramming medium (“MRM”) comprising potassium ion at a concentration of about 30 mM to about 100 mM.
2-5. (canceled)
(canceled)
(canceled)
11-14. (canceled)
16-17. (canceled)
19-20. (canceled)
22-25. (canceled)
27-31. (canceled)
33-34. (canceled)
36-45. (canceled)
A method of expanding TILs obtained from a human subject comprising:
- a. culturing the TILs in an initial TIL culture media;
- b. culturing the TILs in a secondary TIL culture media;
- c. culturing the TILs in a third (or final) TIL culture media,
- wherein the initial TIL culture media, the secondary TIL expansion media, and/or the third TIL expansion media are MRM.
48-52. (canceled)
55-57. (canceled)
59-62. (canceled)
64-65. (canceled)
(canceled)
A composition comprising a population of immune cells, wherein at least about 30% of the immune cells are CD8+ TILs.
69-81. (canceled)
83-151. (canceled)
153-155. (canceled)
Dependencies are inferred from the claim text.